Tender

GMCA 399- Life Sciences Venture Capital Investment Fund 2 for Greater Manchester, Cheshire and Warrington

GREATER MANCHESTER COMBINED AUTHORITY

This public procurement record has 1 release in its history.

Tender

15 Dec 2021 at 12:27

Summary of the contracting process

The Greater Manchester Combined Authority (GMCA) is seeking a Fund Manager for the "Life Sciences Venture Capital Investment Fund 2" aimed at Greater Manchester, Cheshire, and Warrington. This procurement process is currently at the Tender stage, with a deadline for submissions set for 31st January 2022. The fund, valued between £20 million and £25 million, will focus on financial and insurance services, particularly targeting life sciences businesses. The contract period is expected to commence on 8th March 2022 and run until 7th March 2037.

This tender presents significant opportunities for businesses in the life sciences sector, especially those capable of providing fund management services and investor partnerships. Companies with expertise in venture capital, investment in unlisted life science firms, and a robust understanding of public sector funding requirements will be well-suited to compete. With substantial investment committed and an ongoing demand for support from life sciences SMEs in the region, successful bidders can facilitate economic growth and innovation while capitalising on a thriving sector.

Find more tenders on our Open Data Platform.
How relevant is this notice?

D3 Tenders Premium

Win More Public Sector Contracts

AI-powered tender discovery, pipeline management, and market intelligence — everything you need to grow your public sector business.

Notice Title

GMCA 399- Life Sciences Venture Capital Investment Fund 2 for Greater Manchester, Cheshire and Warrington

Notice Description

The contract is for the provision of fund management services to a proposed Life Sciences Venture Capital Investment Fund 2 for Greater Manchester, Cheshire and Warrington (working title for 'LSF2'). It is expected that the Fund Manager will bring both significant experience and knowledge of the venture capital funding market with specific expertise in life science investment in unlisted companies, and also an understanding of public sector sourced funding requirements. The Fund Manager will lead on the investment of the fund and how it will be managed to provide a long term sustainable model. The Fund manager will also be expected to raise further funding from the private sector for each investment it makes. The value of the Fund to be managed is likely to be between 20 000 000 GBP - 25 000 000 GBP. There is no maximum fund size and it is open to other participants. The contract will be placed with a Limited Partnership vehicle which is yet to be created. The various investor partners will take a limited partnership interest and the successful contractor will, probably through a subsidiary entity, be required to take on the General Partner role. Additional information: The Greater Manchester Combined Authority (GMCA), Alderley Park Holdings Limited (a subsidiary of Bruntwood Group Limited), and Cheshire and Warrington Local Enterprise Partnership are being supported by GMCA Commercial Services in the procurement exercise to procure a Fund Manager and General Partner to manage and raise funds. Whilst there are no requirements for Tenderers to take a specific legal form for the purposes of the procurement process, the contract will be entered into as a Limited Partnership vehicle under English law which is yet to be created. The various investor partners will take limited partnership interests in the vehicle (this may be directly or indirectly through another vehicle) and the successful contractor will, probably through a subsidiary entity, be required to take on the General Partner role. In line with national and local policy, Life Sciences are a key growth sector for Greater Manchester. It identified this in the Strategic Economic Plans and have worked together with private sector partners to develop a joint investment fund to provide necessary investment funding for life science companies located in the sub-region. The Fund will invest in "Life Science" businesses covering both human and veterinary applications. These sectors include all stages of development, through to product manufacturing/services provision. Investments are to be permitted in businesses supplying technology products/services to any of the sectors listed above. The Fund will operate within the Greater Manchester and Cheshire and Warrington Local Enterprise Partnership areas (the "Target Area"). The Target Area has significant assets and coherent economic development and spatial strategies to support the ongoing development of a Life Sciences cluster. The Investors established a similar fund in 2015, the "LSF1", which has a life span of 15 years. It took a similar form as envisaged for LSF2 and had an investment fund size of PS37m. LSF1 closed to new investments in June 2021 having made investments into 42 entities. Realisations from LSF1 are due to be made between 2025 and 2030. The Investors believe LSF1 demonstrated an unmet demand for support from Life Sciences SMEs. Based on the applications received by the fund manager for LSF1, there is evidence of a continued and increasing flow of Life Sciences SMEs seeking equity investments in the Target Area, with consultations indicating a level of unmet demand. Research also indicates that the current investment architecture within the Target Area still does not cover the likely needs of Life Science businesses. The proposed Fund will aim to address this market failure and enable partners in the Target Area to play their parts in encouraging business investment in innovation, facilitating networks, cluster development and knowledge exchange, and building a high quality Life Sciences ecosystem. It is envisaged that the Fund will elect to be designated as a Private Fund Limited Partnership ("PFLP"). It is expected that the general partner of the Limited Partnership will be an entity in the same group as the Fund Manager. The investments are likely to be principally in the form of equity or quasi equity as investee companies will almost certainly be at too early a stage in their growth cycle to be able to service debt financing. The Investors have committed to a minimum investment of PS20m, and this could increase to PS25m depending on the realisations made from LSF1. Based on a Fund size of PS20m, the non-financial minimum objectives of the Fund are currently: * support the creation/safeguarding of 500 net jobs over 15 years; * invest in firms that generate PS40.0m GVA pa by the end of 15 years; and * Leverage of PS30m of additional investment at the deal level. The long term objective is to create a 'legacy fund' (after repaying those Limited Partners which require a repayment of their capital and loans) for investment in Life Sciences in the Target Area. Such a legacy fund is not covered by this procurement process.

Publication & Lifecycle

Open Contracting ID
ocds-b5fd17-2325f358-401f-4d50-8415-82ce855f8ee2
Publication Source
Contracts Finder
Latest Notice
https://www.contractsfinder.service.gov.uk/Notice/fa6f3757-500b-4680-99db-622f1a4244a7
Current Stage
Tender
All Stages
Tender

Procurement Classification

Notice Type
Tender Notice
Procurement Type
Standard
Procurement Category
Services
Procurement Method
Open
Procurement Method Details
Open procedure
Tender Suitability
SME, VCSE
Awardee Scale
Not specified

Common Procurement Vocabulary (CPV)

CPV Divisions

66 - Financial and insurance services

79 - Business services: law, marketing, consulting, recruitment, printing and security


CPV Codes

66000000 - Financial and insurance services

79000000 - Business services: law, marketing, consulting, recruitment, printing and security

Notice Value(s)

Tender Value
£10,000,000 £10M-£100M
Lots Value
Not specified
Awards Value
Not specified
Contracts Value
Not specified

Notice Dates

Publication Date
15 Dec 20214 years ago
Submission Deadline
31 Jan 2022Expired
Future Notice Date
Not specified
Award Date
Not specified
Contract Period
8 Mar 2022 - 7 Mar 2037 Over 5 years
Recurrence
Not specified

Notice Status

Tender Status
Active
Lots Status
Not Specified
Awards Status
Not Specified
Contracts Status
Not Specified

Contracting Authority (Buyer)

Main Buyer
GREATER MANCHESTER COMBINED AUTHORITY
Contact Name
Available with D3 Tenders Premium →
Contact Email
Available with D3 Tenders Premium →
Contact Phone
Available with D3 Tenders Premium →

Buyer Location

Locality
MANCHESTER
Postcode
M1 6EU
Post Town
Manchester
Country
England

Major Region (ITL 1)
TLD North West (England)
Basic Region (ITL 2)
TLD3 Greater Manchester
Small Region (ITL 3)
TLD33 Manchester
Delivery Location
TLC North East (England), TLD North West (England), TLF East Midlands (England), TLG West Midlands (England), TLH East (England), TLJ South East (England), TLK South West (England)

Local Authority
Manchester
Electoral Ward
Deansgate
Westminster Constituency
Manchester Central

Further Information

Notice Documents

Open Contracting Data Standard (OCDS)

View full OCDS Record for this contracting process

Download

The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.

{
    "tag": [
        "compiled"
    ],
    "id": "ocds-b5fd17-2325f358-401f-4d50-8415-82ce855f8ee2-2021-12-15T12:27:39Z",
    "date": "2021-12-15T12:27:39Z",
    "ocid": "ocds-b5fd17-2325f358-401f-4d50-8415-82ce855f8ee2",
    "language": "en",
    "initiationType": "tender",
    "tender": {
        "id": "GMCA001-DN587790-12025013",
        "title": "GMCA 399- Life Sciences Venture Capital Investment Fund 2 for Greater Manchester, Cheshire and Warrington",
        "description": "The contract is for the provision of fund management services to a proposed Life Sciences Venture Capital Investment Fund 2 for Greater Manchester, Cheshire and Warrington (working title for 'LSF2'). It is expected that the Fund Manager will bring both significant experience and knowledge of the venture capital funding market with specific expertise in life science investment in unlisted companies, and also an understanding of public sector sourced funding requirements. The Fund Manager will lead on the investment of the fund and how it will be managed to provide a long term sustainable model. The Fund manager will also be expected to raise further funding from the private sector for each investment it makes. The value of the Fund to be managed is likely to be between 20 000 000 GBP - 25 000 000 GBP. There is no maximum fund size and it is open to other participants. The contract will be placed with a Limited Partnership vehicle which is yet to be created. The various investor partners will take a limited partnership interest and the successful contractor will, probably through a subsidiary entity, be required to take on the General Partner role. Additional information: The Greater Manchester Combined Authority (GMCA), Alderley Park Holdings Limited (a subsidiary of Bruntwood Group Limited), and Cheshire and Warrington Local Enterprise Partnership are being supported by GMCA Commercial Services in the procurement exercise to procure a Fund Manager and General Partner to manage and raise funds. Whilst there are no requirements for Tenderers to take a specific legal form for the purposes of the procurement process, the contract will be entered into as a Limited Partnership vehicle under English law which is yet to be created. The various investor partners will take limited partnership interests in the vehicle (this may be directly or indirectly through another vehicle) and the successful contractor will, probably through a subsidiary entity, be required to take on the General Partner role. In line with national and local policy, Life Sciences are a key growth sector for Greater Manchester. It identified this in the Strategic Economic Plans and have worked together with private sector partners to develop a joint investment fund to provide necessary investment funding for life science companies located in the sub-region. The Fund will invest in \"Life Science\" businesses covering both human and veterinary applications. These sectors include all stages of development, through to product manufacturing/services provision. Investments are to be permitted in businesses supplying technology products/services to any of the sectors listed above. The Fund will operate within the Greater Manchester and Cheshire and Warrington Local Enterprise Partnership areas (the \"Target Area\"). The Target Area has significant assets and coherent economic development and spatial strategies to support the ongoing development of a Life Sciences cluster. The Investors established a similar fund in 2015, the \"LSF1\", which has a life span of 15 years. It took a similar form as envisaged for LSF2 and had an investment fund size of PS37m. LSF1 closed to new investments in June 2021 having made investments into 42 entities. Realisations from LSF1 are due to be made between 2025 and 2030. The Investors believe LSF1 demonstrated an unmet demand for support from Life Sciences SMEs. Based on the applications received by the fund manager for LSF1, there is evidence of a continued and increasing flow of Life Sciences SMEs seeking equity investments in the Target Area, with consultations indicating a level of unmet demand. Research also indicates that the current investment architecture within the Target Area still does not cover the likely needs of Life Science businesses. The proposed Fund will aim to address this market failure and enable partners in the Target Area to play their parts in encouraging business investment in innovation, facilitating networks, cluster development and knowledge exchange, and building a high quality Life Sciences ecosystem. It is envisaged that the Fund will elect to be designated as a Private Fund Limited Partnership (\"PFLP\"). It is expected that the general partner of the Limited Partnership will be an entity in the same group as the Fund Manager. The investments are likely to be principally in the form of equity or quasi equity as investee companies will almost certainly be at too early a stage in their growth cycle to be able to service debt financing. The Investors have committed to a minimum investment of PS20m, and this could increase to PS25m depending on the realisations made from LSF1. Based on a Fund size of PS20m, the non-financial minimum objectives of the Fund are currently: * support the creation/safeguarding of 500 net jobs over 15 years; * invest in firms that generate PS40.0m GVA pa by the end of 15 years; and * Leverage of PS30m of additional investment at the deal level. The long term objective is to create a 'legacy fund' (after repaying those Limited Partners which require a repayment of their capital and loans) for investment in Life Sciences in the Target Area. Such a legacy fund is not covered by this procurement process.",
        "datePublished": "2021-12-15T12:27:39Z",
        "status": "active",
        "classification": {
            "scheme": "CPV",
            "id": "66000000",
            "description": "Financial and insurance services"
        },
        "additionalClassifications": [
            {
                "scheme": "CPV",
                "id": "79000000",
                "description": "Business services: law, marketing, consulting, recruitment, printing and security"
            }
        ],
        "items": [
            {
                "id": "1",
                "deliveryAddresses": [
                    {
                        "region": "England",
                        "countryName": "United Kingdom"
                    }
                ]
            }
        ],
        "minValue": {
            "amount": 4000000,
            "currency": "GBP"
        },
        "value": {
            "amount": 10000000,
            "currency": "GBP"
        },
        "procurementMethod": "open",
        "procurementMethodDetails": "Open procedure",
        "tenderPeriod": {
            "endDate": "2022-01-31T10:00:00Z"
        },
        "contractPeriod": {
            "startDate": "2022-03-08T00:00:00Z",
            "endDate": "2037-03-07T23:59:59Z"
        },
        "suitability": {
            "sme": true,
            "vcse": true
        },
        "mainProcurementCategory": "services",
        "documents": [
            {
                "id": "1",
                "documentType": "tenderNotice",
                "description": "Opportunity notice on Contracts Finder",
                "url": "https://www.contractsfinder.service.gov.uk/Notice/fa6f3757-500b-4680-99db-622f1a4244a7",
                "datePublished": "2021-12-15T12:27:39Z",
                "format": "text/html",
                "language": "en"
            }
        ]
    },
    "parties": [
        {
            "id": "GB-CFS-170514",
            "name": "Greater Manchester Combined Authority",
            "identifier": {
                "legalName": "Greater Manchester Combined Authority"
            },
            "address": {
                "streetAddress": "GMCA Offices, 1st Floor, Churchgate House, 56 Oxford Street",
                "locality": "Manchester",
                "postalCode": "M1 6EU",
                "countryName": "England"
            },
            "contactPoint": {
                "name": "Rachel Taylor",
                "email": "rachel.taylor@greatermanchester-ca.gov.uk",
                "telephone": "+44 7725479086"
            },
            "details": {
                "url": "http://www.manchesterfire.gov.uk/"
            },
            "roles": [
                "buyer"
            ]
        }
    ],
    "buyer": {
        "id": "GB-CFS-170514",
        "name": "Greater Manchester Combined Authority"
    }
}